Recent FDA Action Validates ADVEXIN
Selected Abstract
Recent FDA Action Validates ADVEXIN(R) Registration Strategy; Introgen Encouraged By Approval of Erbitux(R) for Head and Neck Cancer.
AUSTIN, Texas, March 3 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. said today it is encouraged by the recent U.S. Food and Drug Administration (FDA) action approving a new therapy for patients who suffer from head and neck cancer. This affirms the approval approach taken by Introgen in ... March 3, 2006; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Recent FDA Action Validates ADVEXIN(R) Registration Strategy; Introgen Encouraged By Approval of Erbitux(R) for Head and Neck Cancer.
|
